Cibisatamab

DB17349InvestigationalProtein Based Therapies

Cibisatamab: Overview.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain, Cell adhesion molecule CEACAM5, and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: Anti-cea/cd3 bispecific antibody ro6958688 · Cea cd3 tcb · CEA TCB · Humanized immunoglobulin g1 (igg1) t-cell bispecific (tcb) antibody targeting carcinoembryonic antigen (cea) and cd3 epsilon chain (cd3e) on t-cells
Code names: RG-7802 · RO-6958688

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cibisatamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.